• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 20-F/A filed by Burning Rock Biotech Limited

    11/26/24 8:24:32 AM ET
    $BNR
    Medical Specialities
    Health Care
    Get the next $BNR alert in real time by email
    FORM 20-F AMENDMENT NO. 1
    20-F/AtrueFY0001792267true 0001792267 2023-01-01 2023-12-31 0001792267 dei:BusinessContactMember 2023-01-01 2023-12-31 0001792267 us-gaap:CommonClassAMember 2023-01-01 2023-12-31 0001792267 dei:AdrMember 2023-01-01 2023-12-31 0001792267 us-gaap:CommonClassAMember 2023-12-31 0001792267 dei:AdrMember 2023-12-31 0001792267 us-gaap:CommonClassBMember 2023-12-31 xbrli:shares
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    FORM 
    20-F
     
     
    (Amendment No. 1)
    (Mark One)
    ☐
    REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
    OR
     
    ☒
    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023
    OR
     
    ☐
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    OR
     
    ☐
    SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    Date of event requiring this shell company report ____________
    For the transition period from __________ to ___________
    Commission file number:
    001-39316
     
     
    Burning Rock Biotech Limited
    (Exact name of Registrant as specified in its charter)
     
     
    N/A
    (Translation of Registrant’s name into English)
    Cayman Islands
    (Jurisdiction of incorporation or organization)
    No.5 Xingdao Ring Road North
    ,
    International Bio Island
    ,
    Guangzhou
    ,
    510005
    The People’s Republic of
    China
    (Address of principal executive offices)
    Ms. Xiaozhi Hu
    , Senior Director in Finance
    Telephone: +86
    020
    -
    3403
    7871
    Email:
    [email protected]
    No.5 Xingdao Ring Road North
    ,
    International Bio Island
    ,
    Guangzhou
    ,
    510005
    The People’s Republic of
    China
    (Name, Telephone,
    E-mail
    and Address of Company Contact Person)
     
     
    Securities registered or to be registered pursuant to Section 12(b) of the Act:
     
    Title of Each Class
     
    Trading
    Symbol(s)
     
    Name of Each Exchange on
    Which Registered
    American depositary shares, each
    representing one Class A ordinary share

    Class A ordinary shares, par value
    US$0.0002 per share*
     
    BNR
     
    The Nasdaq Stock Market LLC
    (The Nasdaq Global Market)
    The Nasdaq Stock Market LLC
    (The Nasdaq Global Market)
     
    *
    Not
    for trading, but only in connection with the listing on the Nasdaq Global Market of American depositary shares.
    Securities registered or to be registered pursuant to Section 12(g) of the Act:
    None
    (Title of Class)
    Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:
    None
    (Title of Class)
     
     
    Indicate the number of issued and outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report: 85,115,600 Class A ordinary shares (excluding (i) the 708,828 Class A ordinary shares issued to the depositary bank for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under share incentive plans, and (ii) 3,023,138 Class A Ordinary Shares as treasury stock) and 17,324,848 Class B ordinary shares, par value US$0.0002 per share, as of December 31, 2023.
    Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  ☐  Yes  ☒  No
    If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. ☐ Yes ☒ No
    Note - Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.
    Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 
    ☒
     Yes ☐ No
    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
    S-T
    (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
    non-accelerated
    filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in
    Rule 12b-2
    of the Exchange Act.
     
    Large accelerated filer   ☐    Accelerated filer   ☒   Non-accelerated filer   ☐
             Emerging growth company   ☐
    If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. ☐
    † The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.
    Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
    If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
    Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to
    §240.10D-1(b). ☐
    Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:
     
    U.S. GAAP ☒     International Financial Reporting Standards as issued         Other ☐
        by the International Accounting Standards Board   ☐      
    If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. Item 17 ☐ Item 18 ☐
    If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in
    Rule 12b-2
    of the Exchange Act). ☐ Yes ☒ No
    (APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)
    Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. ☐ Yes ☐ No
    Auditor Name: Ernst & Young Hua Ming LLP Auditor Location: Guangzhou, the People’s Republic of China PCAOB ID: 1408
     
     
     


    EXPLANATORY NOTE
    This Amendment No. 1 (the “Amendment”) to the Annual Report on Form
    20-F
    of Burning Rock Biotech Limited (the “Company”) for the fiscal year ended December 31, 2023, originally filed with the Securities and Exchange Commission (the “SEC”) on April 29, 2024 (the “Original Filing”), is being filed solely to include revised officers’ certifications contained in Exhibits 12.1 and 12.2 in response to certain comment of the staff of the SEC. This Amendment contains only the cover page, this explanatory note, the exhibit index, the signature page and the revised certifications. Because no financial statements are included with this Amendment, paragraph 3 of the Section 302 certifications has been omitted.
    Except for the foregoing, this Amendment does not alter or update any other information
    contained
    in the Original Filing. The Original Filing continues to speak as of the date of the Original Filing. Accordingly, this Amendment should be read in conjunction with the Original Filing, and the Company’s filings made with the SEC subsequent to the filing of the Original Filing.
     
    i


    PART III

     

    ITEM 18.

    EXHIBITS

     

    Exhibit
    Number
      

    Description of Document

    12.1*    Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
    12.2*    Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
    101.INS†    Inline XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
    101.SCH†    Inline XBRL Taxonomy Extension Schema Document
    101.CAL†    Inline XBRL Taxonomy Extension Calculation Linkbase Document
    101.DEF†    Inline XBRL Taxonomy Extension Definition Linkbase Document
    101.LAB†    Inline XBRL Taxonomy Extension Label Linkbase Document
    101.PRE†    Inline XBRL Taxonomy Extension Presentation Linkbase Document
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    *

    Filed herewith

    † 

    Previously filed with the Original Filing

     

    1


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Burning Rock Biotech Limited
    By:  

    /s/ Yusheng Han

    Name:   Yusheng Han
    Title:   Chairman of the Board of Directors and Chief Executive Officer

    Date: November 26, 2024

     

    2

    Get the next $BNR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BNR

    DatePrice TargetRatingAnalyst
    10/15/2021Outperform
    Cowen
    7/14/2021$39.94Outperform
    CICC
    More analyst ratings

    $BNR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Burning Rock Reports First Quarter 2025 Financial Results

      GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock")), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2025. Recent Business Updates Therapy Selection and MRD Personalized Minimal Residual Disease (MRD) product, CanCatch® Custom supports advancement in oesophageal squamous cell carcinoma(OSCC)treatment, with results published in the Molecular Cancer in May 2025. The study is a two-arm, multicenter, randomized, doub

      6/6/25 3:31:54 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results

      GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock")), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported unaudited financial results for the three months and the year ended December 31, 2024. 2024 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well underway Early Detection   THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Dete

      3/25/25 7:45:42 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Announces Results of 2024 Annual General Meeting

      GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2024 be ratified and that the directors of the Company be authorize

      12/31/24 4:56:17 AM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    SEC Filings

    See more
    • SEC Form 6-K filed by Burning Rock Biotech Limited

      6-K - Burning Rock Biotech Ltd (0001792267) (Filer)

      6/6/25 6:07:22 AM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form 20-F filed by Burning Rock Biotech Limited

      20-F - Burning Rock Biotech Ltd (0001792267) (Filer)

      4/29/25 6:31:11 AM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by Burning Rock Biotech Limited

      6-K - Burning Rock Biotech Ltd (0001792267) (Filer)

      3/25/25 8:14:01 AM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cowen resumed coverage on Burning Rock Biotech

      Cowen resumed coverage of Burning Rock Biotech with a rating of Outperform

      10/15/21 7:18:12 AM ET
      $BNR
      Medical Specialities
      Health Care
    • CICC initiated coverage on Burning Rock Biotech with a new price target

      CICC initiated coverage of Burning Rock Biotech with a rating of Outperform and set a new price target of $39.94

      7/14/21 5:44:04 AM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Leadership Updates

    Live Leadership Updates

    See more
    • Burning Rock Announces Results of 2024 Annual General Meeting

      GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2024 be ratified and that the directors of the Company be authorize

      12/31/24 4:56:17 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024

      GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting ("AGM") on December 31, 2024 at 10:00 a.m. (local time) at the Company's Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company's website, within Investors Relation section, at https://ir.brbiotech.com. The AG

      12/3/24 6:45:12 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Announces Results of 2023 Annual General Meeting

      GUANGZHOU, China, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2023 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: To ratify the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2023 and to authorize the directors of the Company to determine the remuneration of the auditor;To re-elect Wendy Hayes,

      12/19/23 9:35:05 PM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Burning Rock Biotech Limited

      SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

      11/14/24 12:29:09 PM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

      SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

      2/14/24 4:05:59 PM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

      SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

      2/14/24 12:45:51 PM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Financials

    Live finance-specific insights

    See more
    • Burning Rock Reports First Quarter 2024 Financial Results

      GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Detection and Clinical Application of Tumor DNA Methylation Markers (2024 Edition), showing an impressive performance of ELSA-seq using cfDNA in cancer detection an

      5/29/24 1:34:06 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024

      GUANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2024 before the U.S. market opens on May 29, 2024. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the first quarter of 2024. Please register in advance of the conference using the link provided below and dial in 15 minutes prio

      5/23/24 2:00:00 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results

      GUANGZHOU, China, March 28, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ended December 31, 2023. 2023 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well underway Early Detection   Following the Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for our OverC™ Multi-Cancer Detection

      3/28/24 5:16:22 PM ET
      $BNR
      Medical Specialities
      Health Care